OncoMatch/Clinical Trials/NCT05920798
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Is NCT05920798 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine and Pembrolizumab for fallopian tube carcinosarcoma.
Treatment: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine · Pembrolizumab — This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively known as ovarian cancer) that that has come back (after a period of improvement) (recurrent). Ovarian cancer is the most lethal gynecologic malignancy in the United States. While the majority of patients achieve a remission from ovarian cancer with the combination of aggressive cytoreductive surgery and cytotoxic chemotherapy, over 80% of patients develop recurrence within 3 years of completion of treatment. Additional treatments are needed for recurrence, but the standard treatment modalities are non-curative in nature due to the development of drug resistance. As such, there is a great unmet need for treatment strategies that utilize new mechanisms to which drug resistance does not develop. FRalphaDC is a dendritic cell vaccine that is made from the white blood cells collected from a procedure call apheresis. The white blood cells are treated to make dendritic cells, which will then be incubated with peptides, which are pieces of a protein known as "folate receptor alpha" (FRalpha), a protein that is found in high levels on ovarian cancer cells. Dendritic cell vaccines work by boosting the immune system (a system in the body that protect against infection) to recognize and destroy the tumor cells by targeting the FRalpha protein. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving FRalphaDC vaccine with pembrolizumab may be a safe and effective treatment for recurrent ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior treatment for ovarian cancer with an anti-PD-1 or anti-PD-L1 monoclonal antibody
Lab requirements
Blood counts
Hemoglobin ≥ 8.5 g/dL; ANC ≥ 1000/mm^3; Platelet count ≥ 75,000/mm^3; Lymphocytes ≥ 0.3 x 10^9/L; Monocytes ≥ 0.25 x 10^9/L
Kidney function
Creatinine clearance ≥ 30 mL/min per CKD-EPI equation
Liver function
Total bilirubin ≤ 1.5 x ULN (unless Gilbert's disease, then direct bilirubin ≤ ULN); AST ≤ 3 x ULN
Cardiac function
To be eligible, patients should be NYHA class 2B or better
Hemoglobin ≥ 8.5 g/dL ... ANC ≥ 1000/mm^3 ... Platelet count ≥ 75,000/mm^3 ... Lymphocytes ≥ 0.3 x 10^9/L ... Monocytes ≥ 0.25 x 10^9/L ... Total bilirubin ≤ 1.5 x ULN ... AST ≤ 3 x ULN ... Creatinine clearance ≥ 30 mL/min ... NYHA class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
- Mayo Clinic in Florida · Jacksonville, Florida
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify